DRNA News and Press, Dicerna Pharmaceuticals Inc. From 10/15/21

– Data From PHYOX™2 Pivotal Trial of Nedosiran for Treatment of Primary Hyperoxaluria (PH) Accepted as Late-Breaker Poster Presentation – – Company on Track to Submit Nedosiran New Drug Application (NDA) to the U.S. Food and Drug Administration (FDA...

Dicerna Pharmaceuticals, Inc. (Nasdaq: DRNA), a leading developer of investigational ribonucleic acid interference (RNAi) therapeutics, today announced that two abstracts related to the Company’s clinical development programs have been accepted for poster presentations at the...

– Trial to Evaluate Safety and Tolerability of DCR-AUD in Healthy Volunteers – – Trial Includes Ethanol Interaction Assessments to Evaluate Participants’ Response to Alcohol After Receiving DCR-AUD – Dicerna Pharmaceuticals, Inc. ...

Dicerna Pharmaceuticals, Inc. (Nasdaq: DRNA) (the “Company” or “Dicerna”), a leading developer of investigational ribonucleic acid interference (RNAi) therapeutics, today announced that Douglas M. Fambrough, Ph.D., President and Chief Executive Officer, w...

A few weeks ago, DRNA stock tanked after poor PH2 data from its PHYOX trial. The company plans to change strategy and focus on R&D. They have a decent cash reserve; however, investors need to rethink their DRNA thesis. For further details see: Dicerna's PH2 Failure C...

Image source: The Motley Fool. Dicerna Pharmaceuticals, inc (NASDAQ: DRNA) Q2 2021 Earnings Call Aug 9, 2021 , 8:00 a.m. ET Operator Continue reading For further details see: Dicerna Pharmaceuticals, inc (DRNA) Q2 2021 Earnings Call Trans...

– Reported Positive Top-Line Data From Pivotal PHYOX ™ 2 Clinical Trial of Nedosiran Investigational GalXC ™ RNAi Therapy for Treatment of Primary Hyperoxaluria – – Announced U.S. Food and Drug Administration (FDA) Clearance of Invest...

Shares of Dicerna Pharmaceuticals (NASDAQ: DRNA) , a clinical-stage biopharmaceutical company, are tanking after a phase 2 clinical trial readout with the company's lead candidate, nedosiran. Investors left wondering about the company's next move pushed the stock 27.4% lower as of 2...

Earnings news sparked big moves in individual stocks during Friday's midday trading. Synaptics (NASDAQ:SYNA) and LiveRamp (NYSE:RAMP) both advanced following the release of their quarterly results. Meanwhile, financial figures sent Zogenix (NASDAQ:ZGNX) and Zynga (NASDAQ:ZNGA) reeling. Dicern...

Gainers: Kaixin (NASDAQ:KXIN) +50%. Sphere 3D (NASDAQ:ANY) +42%. Westport Fuel Systems (NASDAQ:WPRT) +25%. SCWorx (NASDAQ:WORX) +24%. Aurinia Pharmaceuticals (NASDAQ:AUPH) +22%. LiveRamp Holdings (NYSE:RAMP) +20%. Grid Dynamics (NASDAQ:GDYN) +19%. Bit Digital (NASDAQ:BTBT) +19%. Switch (NYSE:...